


AMENDMENTIn the Claims

Please note amendments relative to the invention as claimed as follow:

1. (currently amended) A compound product of general formula




in which:

R₁ represents ~~the~~ a stereoisomeric forms-form of the chain



and


~~either~~ R₂ represents a hydrogen atom and R₃ represents ~~the~~ a stereoisomeric forms-form of the chain



or R₂ represents ~~the~~ a stereoisomeric forms-form of the chain chains



or



~~and~~ R₃ represents a hydrogen atom,

and

R represents an $-(\text{Alk})_i-(\text{Cycloalk})$ radical,

for which:

Alk denotes an alkyl radical that means a saturated straight- or branched-chain hydrocarbonaceous radical comprising 1 to 6 carbon atoms,




Cycloalk denotes a cycloalkyl radical that means a saturated cyclic hydrocarbonaceous radical comprising 5 or 6 carbon atoms, and

i is equal to 0 or 1;

or

a stereoisomeric form thereof or pharmaceutically acceptable salt thereof with an inorganic or organic acid.

2. (currently amended) The compound product according to Claim 1 of general formula (IV), (V) or (VI):



in which

R represents an $-(\text{Alk})_i-(\text{Cycloalk})$ radical,

for which:

Alk denotes an alkyl radical that means a saturated straight- or branched-chain hydrocarbonaceous radical comprising 1 to 6 carbon atoms,




Cycloalk denotes a cycloalkyl radical that means a saturated cyclic hydrocarbonaceous radical comprising 5 or 6 carbon atoms, and

i is equal to 0 or 1;

or

a stereoisomeric form thereof or pharmaceutically acceptable salt thereof with an inorganic or organic acid.

3. (currently amended) A compound product according to ~~the preceding claim~~ Claim 1 of general formula (VII), (VIII) or (IX):



in which

R represents an $-(\text{Alk})_i-(\text{Cycloalk})$ radical,

for which:

Alk denotes an alkyl radical that means a saturated straight- or branched-chain hydrocarbonaceous radical comprising 1 to 6 carbon atoms,


Cycloalk denotes a cycloalkyl radical that means a saturated cyclic hydrocarbonaceous radical comprising 5 or 6 carbon atoms, and

i is equal to 0 or 1;

or

a pharmaceutically acceptable salt thereof with an inorganic or organic acid.

4. (currently amended) The compound A ~~product according to Claim 1~~ ~~the preceding claim~~ of general formula (IX):



in which;

R represents an $-(\text{Alk})_i-(\text{Cycloalk})$ radical,

for which:

Alk denotes an alkyl radical that means a saturated straight- or branched-chain hydrocarbonaceous radical comprising 1 to 6 carbon atoms,

Cycloalk denotes a cycloalkyl radical that means a saturated cyclic hydrocarbonaceous radical comprising 5 or 6 carbon atoms, and

i is equal to 0 or 1;

or

a pharmaceutically acceptable salt thereof with an inorganic or organic acid.

5. (currently amended) The compound A ~~product~~ according to ~~claim~~ Claim 1 for which:

R represents an $-(\text{Alk})_i-(\text{Cycloalk})$ radical,

for which:

Alk denotes the methyl radical,

Cycloalk denotes a cyclohexyl radical, and

i is equal to 0 or 1;

or

a stereoisomeric form thereof or pharmaceutically acceptable salt thereof with an inorganic or organic acid.

6. (currently amended) The compound A ~~product~~ according to ~~claim~~ Claim 2 for which:

R represents an $-(\text{Alk})_i-(\text{Cycloalk})$ radical,

for which:

Alk denotes the methyl radical,

Cycloalk denotes a cyclohexyl radical, and

i is equal to 0 or 1;

or

a stereoisomeric form thereof or pharmaceutically acceptable salt thereof with an inorganic or organic acid.

7. (currently amended) The compound A ~~product~~ according to ~~claim~~ Claim 3 for which:

R represents an $-(\text{Alk})_i-(\text{Cycloalk})$ radical,

for which:

Alk denotes the methyl radical,

Cycloalk denotes a cyclohexyl radical, and

i is equal to 0 or 1;

or

a pharmaceutically acceptable salt thereof with an inorganic or organic acid.

8. (currently amended) The compound A ~~product~~ according to ~~claim~~ Claim 4 for which:

R represents an $-(\text{Alk})_i-(\text{Cycloalk})$ radical,

for which:

Alk denotes the methyl radical,

Cycloalk denotes a cyclohexyl radical, and

i is equal to 0 or 1;

or

a pharmaceutically acceptable salt thereof with an inorganic or organic acid.

9. (currently amended) ~~The compound A product according to claim Claim 1 which is selected from the group consisting of:~~

4,4'-O,O-dicyclohexyloyl-2-[(1R,2S,3R)(1,2,3,4-tetrahydroxybutyl)]-5-[(2'S,3'R)(2',3',4'-trihydroxybutyl)]pyrazine, ~~and or~~

4,4'-O,O-di(cyclohexylacetyl)-2-[(1R,2S,3R)(1,2,3,4-tetrahydroxybutyl)]-5-[(2'S,3'R)-(2',3',4'-trihydroxybutyl)]pyrazine,

or


a pharmaceutically acceptable salt thereof with an inorganic or organic acid.

10. (currently amended) The compound according to Claim 1 which is 4,4'-O,O-Dicyclohexyloyl-2-[(1R,2S,3R)(1,2,3,4-tetrahydroxybutyl)]-5-[(2'S,3'R)(2',3',4'-trihydroxybutyl)]pyrazine,

or

a pharmaceutically acceptable salt thereof ~~and its salts~~ with an inorganic or organic acid.

11. (currently amended) A process for the preparation of the compound product according to Claim claim 1, comprising reacting a compound product of general formula:



in which:

Ri1 represents a stereoisomeric form of the chain

$-(\text{CHOH})_3-\text{CH}_2\text{OH}$ (XI),

and

Ri2 represents a hydrogen atom and Ri3 represents a stereoisomeric form of the chain

$-\text{CH}_2-(\text{CHOH})_2-\text{CH}_2\text{OH}$ (XII)

or

Ri2 represents ~~the a~~ stereoisomeric ~~forms form~~ of the chain chains

$-(\text{CHOH})_3-\text{CH}_2\text{OH}$ (XI)

or

$-\text{CH}_2-(\text{CHOH})_2-\text{CH}_2\text{OH}$ (XII),

and Ri3 represents a hydrogen atom,

with an acyl halide of formula R-COX, in which R is defined as in Claim 1 and X represents a halogen atom.

12. (original) The process according to Claim 11, wherein the reaction is carried out in the presence of pyridine between 0 and 40°C.

13. (currently amended) A pharmaceutical composition ~~medicament~~ comprising as ~~active principle~~ a pharmaceutically appropriate dosage of a compound ~~product~~ according to Claim 1 ~~claim 1~~ and ~~an~~ a pharmaceutically compatible excipient.

14. (canceled)

15. (new) A method of preventing or treating glycemia in a human comprising administering to the human a pharmaceutically appropriate dosage of the compound of Claim 1.